Lauren R Cirrincione1, Anthony T Podany1, Joshua P Havens1,2, Sara H Bares2, Shetty Ravi Dyavar1, Yeongjin Gwon3, Tanner M Johnson1, N Jean Amoura4, Courtney V Fletcher1,2, Kimberly K Scarsi1,2. 1. Antiviral Pharmacology Laboratory, Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA. 2. Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA. 3. Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA. 4. Department of Obstetrics and Gynecology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Abstract
BACKGROUND: Transwomen have an increased risk of HIV acquisition compared with other adults. Drug-drug interactions between pre-exposure prophylaxis (PrEP) and gender-affirming therapy are cited as a reason for poor PrEP uptake among transwomen. We evaluated plasma tenofovir and emtricitabine pharmacokinetics and their active intracellular anabolites, tenofovir-diphosphate and emtricitabine-triphosphate, in transwomen receiving feminizing hormones. METHODS: We enrolled HIV-negative transwomen (≥19 years) not receiving PrEP. Participants took oral tenofovir disoproxil fumarate/emtricitabine 300/200 mg daily for 14 days. Plasma was collected at 0 h (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 and 12 h on day 14 post-tenofovir disoproxil fumarate/emtricitabine dose. The plasma AUC0-24 was calculated using the trapezoidal rule and compared with historical HIV-negative cisgender adults as geometric mean ratios (GMRs, 90% CI). Secondarily, tenofovir-diphosphate and emtricitabine-triphosphate from PBMCs collected at 0 h and 12 h were reported descriptively as geometric means (90% CI). Clinical trials registration: NCT03270969. RESULTS: Among 15 transwomen (mean age 32 years), geometric mean tenofovir and emtricitabine plasma AUC0-24 were lower compared with controls: tenofovir, 2.10 versus 2.76 mg·h/L, GMR 0.76 (0.65-0.90), P = 0.01; emtricitabine, 9.15 versus 10.64 mg·h/L, GMR 0.86 (0.75-0.98), P = 0.07. Tenofovir-diphosphate and emtricitabine-triphosphate concentrations were higher than previously reported in the literature: 167.1 (146.6-190.5) fmol/106 cells and 15.4 (13.8-17.3) pmol/106 cells, respectively. CONCLUSIONS: We observed lower plasma tenofovir and emtricitabine concentrations in transwomen compared with historical cisgender adults, yet intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations were higher than previously reported in PBMCs. Understanding the differences of PrEP pharmacokinetics in plasma and tissue compartments and the resultant impact on efficacy remains important for transwomen.
BACKGROUND: Transwomen have an increased risk of HIV acquisition compared with other adults. Drug-drug interactions between pre-exposure prophylaxis (PrEP) and gender-affirming therapy are cited as a reason for poor PrEP uptake among transwomen. We evaluated plasma tenofovir and emtricitabine pharmacokinetics and their active intracellular anabolites, tenofovir-diphosphate and emtricitabine-triphosphate, in transwomen receiving feminizing hormones. METHODS: We enrolled HIV-negative transwomen (≥19 years) not receiving PrEP. Participants took oral tenofovir disoproxil fumarate/emtricitabine 300/200 mg daily for 14 days. Plasma was collected at 0 h (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 and 12 h on day 14 post-tenofovir disoproxil fumarate/emtricitabine dose. The plasma AUC0-24 was calculated using the trapezoidal rule and compared with historical HIV-negative cisgender adults as geometric mean ratios (GMRs, 90% CI). Secondarily, tenofovir-diphosphate and emtricitabine-triphosphate from PBMCs collected at 0 h and 12 h were reported descriptively as geometric means (90% CI). Clinical trials registration: NCT03270969. RESULTS: Among 15 transwomen (mean age 32 years), geometric mean tenofovir and emtricitabine plasma AUC0-24 were lower compared with controls: tenofovir, 2.10 versus 2.76 mg·h/L, GMR 0.76 (0.65-0.90), P = 0.01; emtricitabine, 9.15 versus 10.64 mg·h/L, GMR 0.86 (0.75-0.98), P = 0.07. Tenofovir-diphosphate and emtricitabine-triphosphate concentrations were higher than previously reported in the literature: 167.1 (146.6-190.5) fmol/106 cells and 15.4 (13.8-17.3) pmol/106 cells, respectively. CONCLUSIONS: We observed lower plasma tenofovir and emtricitabine concentrations in transwomen compared with historical cisgender adults, yet intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations were higher than previously reported in PBMCs. Understanding the differences of PrEP pharmacokinetics in plasma and tissue compartments and the resultant impact on efficacy remains important for transwomen.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Sharon M Seifert; David V Glidden; Amie L Meditz; Jose R Castillo-Mancilla; Edward M Gardner; Julie A Predhomme; Caitlin Rower; Brandon Klein; Becky J Kerr; L Anthony Guida; Jia-Hua Zheng; Lane R Bushman; Peter L Anderson Journal: Clin Infect Dis Date: 2014-11-18 Impact factor: 9.079
Authors: Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant Journal: Sci Transl Med Date: 2012-09-12 Impact factor: 17.956
Authors: Jennifer J Kiser; Courtney V Fletcher; Patricia M Flynn; Coleen K Cunningham; Craig M Wilson; Bill G Kapogiannis; Hanna Major-Wilson; Rolando M Viani; Nancy X Liu; Larry R Muenz; D Robert Harris; Peter L Havens Journal: Antimicrob Agents Chemother Date: 2007-11-19 Impact factor: 5.191
Authors: Jessica L Adams; Craig Sykes; Prema Menezes; Heather M A Prince; Kristine B Patterson; Katrien Fransen; Tania Crucitti; Irith De Baetselier; Lut Van Damme; Angela D M Kashuba Journal: J Acquir Immune Defic Syndr Date: 2013-03-01 Impact factor: 3.731
Authors: Mackenzie L Cottrell; Heather M A Prince; Amanda P Schauer; Craig Sykes; Kaitlyn Maffuid; Amanda Poliseno; Tae-Wook Chun; Erin Huiting; Frank Z Stanczyk; Anne F Peery; Evan S Dellon; Jessica L Adams; Cindy Gay; Angela D M Kashuba Journal: Clin Infect Dis Date: 2019-11-27 Impact factor: 9.079
Authors: Eugenie Shieh; Mark A Marzinke; Edward J Fuchs; Allyson Hamlin; Rahul Bakshi; Wutyi Aung; Jennifer Breakey; Tonia Poteat; Todd Brown; Namandjé N Bumpus; Craig W Hendrix Journal: J Int AIDS Soc Date: 2019-11 Impact factor: 5.396
Authors: Melissa E Badowski; Nicholas Britt; Emily C Huesgen; Michelle M Lewis; Misty M Miller; Kathleen Nowak; Elizabeth Sherman; Renata O Smith Journal: Pharmacotherapy Date: 2021-02-27 Impact factor: 4.705
Authors: Rogers Sekabira; Ian McGowan; Krista Yuhas; Rhonda M Brand; Mark A Marzinke; Yukari C Manabe; Ian Frank; Joseph Eron; Raphael J Landovitz; Peter Anton; Ross D Cranston; Peter Anderson; Kenneth H Mayer; K Rivet Amico; Timothy J Wilkin; Wairimu Chege; Adeodata R Kekitiinwa; Marybeth McCauley; Roy M Gulick; Craig W Hendrix Journal: AIDS Date: 2021-08-01 Impact factor: 4.632
Authors: Shetty Ravi Dyavar; Timothy M Mykris; Lee C Winchester; Kimberly K Scarsi; Courtney V Fletcher; Anthony T Podany Journal: Sci Rep Date: 2020-07-28 Impact factor: 4.379